DeCure for Maturity-onset diabetes of the young type 9
DeCure's autonomous Metabolic AI scientist is researching a drug-repurposing hypothesis for maturity-onset diabetes of the young type 9 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMaturity-onset diabetes of the young type 9 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for maturity-onset diabetes of the young type 9 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
Maturity-onset diabetes of the young (MODY) accounts for only 1% to 2% of all diabetes cases and is often misdiagnosed as type 1 or type 2 diabetes. It is a heterogeneous group of disorders that result in β-cell dysfunction. Diagnosis allows appropriate individualised care depending on the genetic etiology and allows prognostication in family members. Pregnancy is a crucial time to diagnose MODY forms because of the 50% risk of inheritance in offspring and the potential implications for adequate fetal weight; both maternal and paternal diabetes inheritance patterns affect birth weight and should be considered for a correct pathogenetic diagnosis.
All recognised MODY forms are dominantly inherited. One hypothesis proposes that recessive MODY variants do exist but have escaped detection because they lack a family history suggestive of monogenic inheritance. The question is whether pancreatic β cells are only harmed by heterozygous variants.
No drug treatment data are reported in these abstracts. No specific drug is mentioned for any MODY subtype, including MODY9. The abstracts discuss diagnosis, genetic inheritance, and the importance of distinguishing MODY from type 1 and type 2 diabetes, but they provide no concrete numbers on survival, response rates, or sample sizes for any intervention.
What is still missing is any clinical trial testing a drug specifically for MODY9, any patient stratification by the underlying genetic variant, and the funding needed to conduct such trials. Without these, the management of MODY9 remains limited to the general principles of diabetes care, not a targeted therapy.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Diabetes Metabolic Syndrome and Obesity · 2012 · 144 citations · open access
Clinical features and treatment of maturity onset diabetes of the young (MODY)
AbstractMaturity onset diabetes of the young (MODY) is a heterogeneous group of disorders that result in β-cell dysfunction. It is rare, accounting for just 1%-2% of all diabetes. It is often misdiagnosed as type 1 or type 2 diabetes, as it is often difficult to distinguish MODY from these two forms. However, diagnosis allows appropriate individualized care, depending on the genetic etiology, and allows prognostication in family members. In this review, we discuss features of the common causes of MODY, as well as the treatment and diagnosis of MODY.
Maternal or Paternal Diabetes and Its Crucial Role in Offspring Birth Weight and MODY Diagnosis
AbstractMaturity-onset diabetes of the young (MODY) represents a heterogenous group of monogenic autosomal dominant diseases, which accounts for 1-2% of all diabetes cases. Pregnancy represents a crucial time to diagnose MODY forms due to the 50% risk of inheritance in offspring of affected subjects and the potential implications on adequate fetal weight. Not only a history of maternal diabetes may affect the birth weight of offspring, paternal diabetes should also be taken into consideration for a correct pathogenetic diagnosis. The crucial role of maternal and paternal diabetes inheritance patterns and the impact of this inherited mutation on birthweight and the MODY diagnosis was discussed.
Why all MODY variants are dominantly inherited: a hypothesis.
AbstractMaturity-onset diabetes in the young (MODY) comprises monogenic phenotypes of young-onset, insulinopenic diabetes. All its forms are dominantly inherited. Why? Are the pancreatic β cells only harmed by heterozygous variants? We propose that recessive MODYs do exist but have escaped detection due to lack of family history suggestive of monogenic inheritance.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
